| Source: |
| Type: |
| P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is a membrane protein that plays a crucial role in the transport of various substances across cellular membranes. It is part of the ATP-binding cassette (ABC) transporter family. P-glycoprotein is often overexpressed in a variety of cancers, including breast cancer, lung cancer, leukemia, and ovarian cancer. - The overexpression of P-glycoprotein (P-gp), is widely considered as an important reason for the MDR (multidrug resistance). ABCB1 - ATP-Binding Cassette Subfamily B Member 1 / P-Glycoprotein Abbreviation: ABCB1, P-gp, P-glycoprotein, MDR1 Type: ATP-dependent membrane efflux transporter / multidrug resistance protein Function: ABCB1 encodes P-glycoprotein, an ATP-binding cassette transporter that exports a broad range of drugs, xenobiotics, lipids, and other substrates across cellular membranes. It is highly expressed in barrier tissues including the intestine, liver, kidney, placenta, and blood-brain barrier, where it limits tissue accumulation of potentially harmful compounds. Cancer: ↑ Frequently overexpressed or functionally activated in drug-resistant tumors. Increased ABCB1 lowers intracellular concentrations of many anticancer agents by actively transporting them out of cancer cells, producing multidrug resistance and reducing chemotherapy effectiveness. Alzheimer's Disease: ↓ Reduced ABCB1/P-glycoprotein expression or transport activity at the blood-brain barrier is associated with impaired amyloid-β clearance from the brain. Lower P-gp function correlates with increased cerebral Aβ accumulation and may contribute to Alzheimer's disease progression. |
| 5640- | BCA, | Improved effectiveness of biochanin A as a P-gp inhibitor in solid dispersion |
| - | in-vitro, | Nor, | NA |
| 3697- | BM, | Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 5649- | BNL, | Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability |
| - | Review, | Nor, | NA |
| 5650- | BNL, | Borneol Depresses P-Glycoprotein Function by a NF-κB Signaling Mediated Mechanism in a Blood Brain Barrier in Vitro Model |
| - | in-vivo, | Nor, | NA |
| 5666- | BNL, | Exploring the potential to enhance drug distribution in the brain subregion via intranasal delivery of nanoemulsion in combination with borneol as a guider |
| - | in-vivo, | AD, | NA |
| 5669- | BNL, | Comparison of pharmacological activity and safety of different stereochemical configurations of borneol: L-borneol, D-borneol, and synthetic borneol |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 8080- | KAE, | Hepatoprotective Effect of Kaempferol—A Review |
| - | Review, | Nor, | NA |
| 8252- | LCA, | Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. |
| - | in-vivo, | Nor, | NA |
| 8216- | LCA, | Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A |
| - | in-vivo, | Nor, | NA |
| 8902- | MOR, | Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats |
| - | vitro+vivo, | Nor, | NA |
| 3646- | SIL, | "Silymarin", a promising pharmacological agent for treatment of diseases |
| - | Review, | Var, | NA |
| 6460- | TUR, | CUR, | Neuroprotective Effect of Turmeric Extract in Combination with Its Essential Oil and Enhanced Brain Bioavailability in an Animal Model |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:1 prod#:% Target#:232 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid